References
- Jelkmann W. Regulation of erythropoietin production. J Physiol (Lond) 2011;589:1251–8.
- Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33:891–6.
- Lonnberg M, Garle M, Lonnberg L, Birgegard G. Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis. J Pharm Biomed Anal 2013;8182:187–92.
- Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, Lee SD. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol 2003;18:1156–61.
- Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract 2012;2012:539412.
- Gluud C. Serum testosterone concentrations in men with alcoholic cirrhosis: background for variation. Metab Clin Exp 1987;36:373–8.
- Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009;85:44–54.
- Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326–32.
- Laffi G, La VG, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997;17:530–48.
- Nouh MA, Hossam M, Emad H, Ashraf S, Wafaa E, Reham S. Study of plasma erythropoietin hormone level in patients with liver cirrhosis. Researcher 2015;3:78–83.
- Siciliano M, Tomasello D, Milani A, Ricerca BM, Storti S, Rossi L. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995;22:1132–5.
- Li XJ, Zhang GX, Sun N, Sun Y, Yang LZ, Du YJ. Protective effects of erythropoietin on endotoxin-related organ injury in rats. J Huazhong Univ Sci Technol Med Sci 2013;33:680–6.
- Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326–33.
- Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol 2006;39:16–21.
- Zhang Z, Zhang F, Lu Y, Zheng S. Update on implications and mechanisms of angiogenesis in liver fibrosis. Hepatol Res 2015;45:162–78.
- Siciliano M, Tomasello D, Milani A, Ricerca BM, Storti S, Rossi L. Erythropoietin secretion in liver disease. Clin Chim Acta 1995;236:217–18.
- Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int 2009;75:682–8.
- Gabius HJ. Biological information transfer beyond the genetic code: the sugar code. Naturwissenschaften 2000;87:108–21.
- Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012;6:163–89.